Plain-English translation of NCT07284472 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing two experimental medications— and —to see if they can safely reduce agitation in people with Alzheimer's disease. Agitation (restlessness, irritability, and aggression) is a common and distressing symptom in Alzheimer's, and this study aims to find a better treatment option. About 300 people will participate across 60 research centers in the United States, Canada, and Europe.
Agitation is a serious problem for many people with Alzheimer's disease and their caregivers, but current treatment options are limited. This medication is being tested to see if it offers a safer and more effective way to help manage these symptoms.
You likely qualify if…
You likely don't qualify if…
You would take capsules by mouth twice daily for 6 weeks—either the new medication or a placebo (inactive pill). You'll have a screening visit about 4 weeks before starting treatment, where researchers will confirm you qualify. Throughout the study, your caregiver will help track how you're doing, and the research team will monitor your safety and whether the treatment is helping with agitation.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States